

Molecular Diagnostics

Part I: Technologies & Applications

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

December 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His books include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011; 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese edition 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed Chemical Industry Press 2016, 2nd ed 2017), "Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011)", "Applications of Biotechnology in Neurology (Springer, 2013)", and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first commercial report on DNA Diagnostics in 1995, which was published by PJB Publication, London. This was updated in 1997 as Molecular Diagnostics I and the next edition, Molecular Diagnostics II, was published in 1999 – both by Decision Resources Inc, USA. All the three versions of the reports were well accepted and sold widely. The current version was originally published by Jain PharmaBiotech in 2001 and is constantly updated and revised since then. Not only was this the first such report on molecular diagnostics, it is the longest continuously published report on this topic (20 years). It is also the most comprehensive and detailed report on this topic containing profiles of the largest number of companies involved in molecular diagnostics.

December 2017 (continuously published since 1995)
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	25
1. Introduction	27
Definitions and scope of the subject	27
Historical evolution of molecular diagnostics.....	27
Molecular biology relevant to molecular diagnostics.....	28
DNA	28
<i>DNA polymerases.....</i>	28
<i>Restriction endonucleases.....</i>	29
RNA	29
<i>RNA polymerases.....</i>	29
<i>Non-coding RNAs.....</i>	30
DNA transcription.....	30
Chromosomes	30
<i>Chromatin.....</i>	31
Telomeres.....	31
Mitochondrial DNA	31
Genes.....	32
<i>The genetic code.....</i>	32
<i>Gene expression</i>	32
The human genome	33
<i>ENCODE</i>	33
Variations in the human genome.....	34
<i>Variations in DNA sequences</i>	34
<i>Single nucleotide polymorphisms</i>	35
Haplotyping.....	35
<i>Copy number variations in the human genome</i>	36
<i>Genotype and haplotypes.....</i>	37
<i>Insertions and deletions in the human genome.....</i>	37
<i>Complex chromosomal rearrangements</i>	38
<i>Large scale variation in human genome</i>	39
<i>Structural variations in the human genome</i>	39
<i>Replication of the DNA helix</i>	39
<i>Transposons.....</i>	40
Epigenetics/epigenomics	40
<i>DNA methylation.....</i>	40
Proteins	41
Proteomics.....	41
Monoclonal antibodies	42
Aptamers.....	42
Basics of molecular diagnostics	42
Tracking DNA: the Southern blot	43
Pulsed-field gel electrophoresis.....	43
DNA Probes.....	43
The polymerase chain reaction	44
<i>Basic Principles of PCR.....</i>	44
<i>Target selection</i>	44
<i>Detection of amplified DNA.....</i>	45
Impact of human genome project on molecular diagnostics	45
<i>Mapping and sequencing of structural variation from human genomes.....</i>	46
1000 Genomes Project	46
<i>Human Variome Project.....</i>	47
Role of bioinformatics in molecular diagnostics.....	48
Systems biology approach to molecular diagnostics	48
Synthetic biology and molecular diagnostics	49
Biomarkers	49
Applications of molecular diagnostics.....	50
2. Molecular Diagnostic Technologies	53
Introduction	53
DNA sample collection and extraction.....	53
Blood samples	53
Buccal swabs and saliva.....	53
Dried blood spots.....	54
Formalin-fixed, paraffin-embedded tissues	54
Manual vs automated DNA extraction	55

Urine samples for transrenal DNA	55
Sample preparation	56
Pressure Cycling Technology	56
Membrane immobilization of nucleic acids.....	56
Automation of sample preparation in molecular diagnostics.....	57
ABI PRISM 6700 Automated Nucleic Acid Workstation	57
BioRobot technology.....	57
COBAS AmpliPrep System.....	57
GENESIS FE500 Workcell	57
GeneMole.....	58
PCR BioCube	58
QIASymphony.....	58
Tigris instrument system	58
Techniques for sample preparation suitable for automation	59
<i>Xtra Amp Genomic DNA Extraction</i>	59
<i>Extraction of DNA from paraffin sections</i>	59
<i>Dynabead technology</i>	59
<i>SamPrep</i>	60
Use of magnetic particles for automation in genome analysis	60
Companies involved in nucleic acid isolation	60
Labeling and detection of nucleic acids.....	62
Novel PCR methods.....	62
Addressing limitations of PCR	62
Cooperative primer	62
ARMS-PCR	63
CAST-PCR	63
Combined PCR-ELISA	63
Convection PCR	64
Digital PCR.....	64
Dumbbell PCR	65
Emulsion PCR.....	65
ExCyto PCR.....	66
Fast PCR.....	66
Immuno PCR.....	66
Long and accurate PCR.....	67
Multiplex PCR	67
Overlap extension PCR	67
Real-time PCR systems.....	67
<i>Dyes used in real-time PCR</i>	68
<i>Target-specific fluorogenic probes for monitoring real-time PCR</i>	69
<i>Applications of real-time PCR</i>	69
<i>Limitations of real-time PCR</i>	70
<i>Quantitative PCR for accurate low level DNA analysis</i>	70
<i>qPCR for quantification of mtDNA</i>	70
<i>Real-time qPCR for measuring the length of telomeres</i>	71
<i>Guidelines for real-time qPCR</i>	71
<i>Future applications of real-time qPCR</i>	71
Commercially available real-time PCR systems	72
<i>Life Technologies' Real-Time PCR systems</i>	72
<i>LightCycler PCR system</i>	73
<i>LightUp probes based on real-time PCR</i>	73
<i>MNAzyme qPCR</i>	74
<i>READ™ real-time PCR method</i>	75
<i>StellARray™ technology</i>	75
Reverse hybridization PCR assays	75
Reverse transcriptase (RT)-PCR.....	75
<i>Standardized reverse transcriptase PCR</i>	76
Single cell PCR.....	77
<i>LATE-PCR</i>	77
<i>COLD-PCR</i>	77
<i>AmpliGrid-System</i>	78
Solar thermal PCR system monitored by Smartphone	78
Ultrafast photonic PCR.....	79
DNA melt analysis.....	79
High-resolution DNA melt analysis for genotyping	79
PCR device for DNA melt analysis in space	80
Monitoring of gene amplification in molecular diagnostics	80
Non-PCR nucleic acid amplification methods	80
DNA probes with conjugated minor groove binder	80
DNABLE.....	81

Dynamic Flux Amplification	81
Isothermal nucleic acid amplifications	81
<i>Isothermal reaction for amplification of oligonucleotides</i>	81
<i>Isothermal and chimeric primer-initiated amplification of nucleic acids</i>	82
<i>Loop-mediated amplification</i>	82
<i>Single Primer Isothermal Amplification</i>	82
<i>Strand Invasion Based Amplification</i>	83
Linked Linear Amplification.....	83
Multiplex Ligation-Dependent Probe Amplification	83
Rapid analysis of gene expression	83
Recombinase polymerase amplification	84
Rolling circle amplification technology.....	84
<i>Gene-based diagnostics through RCAT</i>	85
<i>RCAT-immunodiagnosics</i>	86
<i>RCAT-pharmacogenomics</i>	86
<i>Circle-to-circle amplification</i>	86
Ramification amplification method.....	86
Transcription mediated amplification	87
WAVE nucleic acid fragment analysis system	87
Technologies for signal amplification	88
3 DNA dendrimer signal amplification	88
Hybridization signal amplification method	89
Signal mediated amplification of RNA technology	90
Invader assays	91
Hybrid Capture technology	92
Branched DNA test.....	93
Tyramide signal amplification	93
Non-enzymatic signal amplification technologies	93
Non-PCR methods for molecular diagnosis	94
Direct molecular analysis without amplification	95
<i>Trilogy™ Platform</i>	95
<i>Direct detection of dsDNA</i>	96
Multiplex assays	96
Fluorescent in situ hybridization	96
FISH technique	97
Applications of FISH	98
Modifications of FISH.....	99
Direct visual in situ hybridization	99
Direct labeled Satellite FISH probes.....	99
Comparative genomic hybridization	99
Primed in situ labeling	100
Interphase FISH	100
FISH with telomere-specific probes	100
Multicolor FISH	101
<i>Simultaneous Ultrasensitive Subpopulation staining/Hybridization In situ</i>	101
Automation of FISH.....	101
Companies involved in FISH diagnostics.....	102
RNA diagnostics	102
RNA isolation from tissue samples.....	103
Commercially available tests for mRNA detection and quantitation	103
Branched-chain DNA assay for measurement of RNA	104
Cycling probe technology	104
Invader RNA assays	104
Linear RNA amplification	105
Non-isotopic RNase cleavage assay	105
Nucleic acid sequence-based amplification	105
Q Beta replicase system	108
RNAScope.....	108
RNA expression profiling	108
<i>Visualization of mRNA expression in vivo</i>	108
Solid Phase Transcription Chain Reaction	109
Transcriptome analysis	109
MicroRNA diagnostics	109
<i>Microarray vs quantitative PCR for measuring miRNAs</i>	110
<i>Microarrays for analysis of miRNA gene expression</i>	110
<i>miR-TRAP to identify miRNA targets in vivo</i>	111
<i>Modification of in situ hybridization for detection of miRNAs</i>	111
<i>Nuclease Protection Assay to measure miRNA expression</i>	112
<i>Real-time PCR for expression profiling of miRNAs</i>	112
<i>Use of LNA to explore miRNA</i>	112

Whole genome amplification.....	113
Companies that provide technologies for whole genome amplification	113
<i>QIAGEN's Repli-G system.....</i>	<i>113</i>
<i>GenomePlex™ Whole Genome Amplification</i>	<i>114</i>
DNA sequencing.....	114
Applications of next generation sequencing in molecular diagnostics	115
Companies developing sequencing for molecular diagnostics	116
Molecular diagnostics and sequencing in space	117
Genome-wide approach for chromatin mapping	118
Mitochondrial sequencing	119
Identification of unknown DNA sequences	119
<i>Mitochondrial exome sequencing.....</i>	<i>120</i>
Optical mapping.....	120
Gene expression analysis.....	120
Gene expression profiling on whole blood samples	121
Gene expression patterns of white blood cells.....	122
Gene expression profiling based on alternative RNA splicing	122
MAUI (MicroArray User Interface) hybridization	123
Monitoring in vivo gene expression by molecular imaging	123
Serial analysis of gene expression (SAGE).....	123
Single-cell gene expression analysis	123
T cell receptor expression analysis	125
Tangerine™ expression profiling	125
Whole genome expression array	125
Ziplex™ system	126
Companies involved in gene expression analysis.....	126
Peptide nucleic acid technology.....	127
Use of PNA with fluorescence in situ hybridization	128
PNA and PCR	129
Use of PNA with biosensors	129
PNA-based PD-loop technology	130
PNA-DNA hybrid quadruplexes.....	130
Companies involved in PNA diagnostics.....	130
Locked nucleic acids	131
Zip Nucleic Acids.....	131
Electrochemical detection of DNA	132
Mediated nucleic acid oxidation.....	132
Detection of hybridized nucleic acid with cyclic voltametry	133
Electrochemical detection based on Toshiba's CMOS technology.....	133
Concluding remarks on electrochemical DNA detection	133
Bead-based assay platforms	134
Scorpions™ technology.....	135
The Scorpions reaction	135
Applications of Scorpions	135
Nucleic acid lateral flow molecular diagnostics.....	136
Omics-based tests	137

3. Biochips, Biosensors, and Nanobiotechnology **139**

Introduction to biochip technology.....	139
Applications of biochips in diagnostics	139
GeneChip.....	140
<i>GeneChip Human Genome Arrays</i>	<i>141</i>
<i>AmpliChip CYP450.....</i>	<i>141</i>
Electronic detection of nucleic acids on microarrays.....	141
Microchip capillary electrophoresis	142
Strand displacement amplification on a biochip.....	142
Rolling circle amplification on microarrays	142
<i>LiquiChip-RCAT.....</i>	<i>142</i>
Fast PCR biochip	143
Multiplex microarray-enhanced PCR for DNA analysis	143
Multiplexed Molecular Profiling	143
Universal DNA microarray combining PCR and ligase detection reaction	144
Genomewide association scans	144
Whole genome chips/microarrays.....	145
Transposon insertion site profiling chip	145
Standardizing the microarrays	146
Companies involved in developing biochip technology for diagnostics	146
Future of biochip technology for molecular diagnostics.....	147
Microfluidic chips	147
Fish-on-chip	148

Lab-on-a-chip.....	148
LabCD	149
Micronics' microfluidic technology.....	149
Microfluidic chips/arrays using PCR	149
<i>Microfluidic automated DNA analysis using PCR</i>	149
<i>Digital PCR Array</i>	149
<i>Digital PCR on a SlipChip</i>	150
Microfluidic chips integrated with RCAT	150
Microfluidic chips integrated with PET	150
Companies developing microfluidic technologies	151
Biosensor technologies	152
Classification of biosensor technologies.....	153
DNA-based biosensors.....	154
<i>DNA hybridization biosensor chips</i>	154
<i>PCR-free DNA biosensor</i>	154
<i>DNA based biosensor to detects metallic ions</i>	155
Genetically engineered B lymphocytes.....	155
Biosensors immunoassays.....	155
PNA (peptide nucleic acid)-based biosensors	156
Protein-based biosensors	156
Antibody biosensors	156
Cell-based biosensors (cytosensors).....	156
<i>Multicell biosensors</i>	157
<i>Microbial biosensors</i>	157
Optical biosensors.....	158
<i>Surface plasmon resonance technology</i>	158
<i>Label-free optical biosensor</i>	159
Microsensors using with nano/microelectronic communications technology.....	159
Electrochemical sensors.....	159
<i>Enzyme electrodes for biosensing</i>	159
<i>Conductometric sensors</i>	160
<i>Electrochemical genosensors</i>	160
<i>Electrochemical nanobiosensor</i>	160
<i>Electrochemical microRNA biosensor</i>	161
Phototransistor biochip biosensor.....	162
Ribozyme-based sensors.....	162
<i>RiboReporters</i>	162
Concluding remarks and future prospects of biosensor technology	163
Companies developing biosensors for molecular diagnostics	164
Molecular labels and detection.....	165
Detection technologies for molecular labels	166
Fluorescence and chemiluminescence	166
<i>Fluorescence technologies for label detection</i>	166
<i>Companies with fluorescence and chemiluminescence products</i>	167
Molecular beacons.....	168
The Green fluorescent protein	169
Multiphoton detection radioimmunoassay	170
Multi-pixel photon counter	170
Enzyme labels and detection by fluorescence	170
Phase-sensitive flow cytometry.....	171
Microtransponder-based DNA diagnostics.....	171
Laboratory Multiple Analyte Profile	172
Multiple labels	172
Protein-DNA chimeras for detection of small numbers of molecules.....	173
Single molecule detection	173
Atomic force microscopy	174
Capillary electrophoresis	174
Confocal laser scanning	174
Time domain optical imaging technology.....	174
nCounter Analysis System.....	175
Spectrally resolved fluorescence lifetime imaging microscopy	175
Molecular imaging	175
Technologies for molecular imaging.....	175
<i>Positron emission tomography</i>	176
<i>Magnetic resonance imaging</i>	176
<i>Optoacoustic imaging</i>	176
<i>Computer tomography</i>	177
<i>Hyperpolarized diazirines for in vivo biomolecular imaging</i>	177
Basic research in molecular imaging	177
Devices for molecular imaging	177

Molecular imaging in clinical practice	178
Companies involved in molecular imaging	178
Nanobiotechnology for molecular diagnostics.....	179
Cantilever arrays	180
Diagnostics based on nanopore technology	181
DNA nanomachines for molecular diagnostics	181
Exosome-based molecular diagnostics	181
Fullerene photodetectors for chemiluminescence detection on microfluidic chip.....	182
Gold nanoparticles	182
Immunoliposome-PCR	182
Magnetic nanoparticles	183
Nanotechnology on a chip	184
NanoChip® Electronic Microarray.....	184
Nanobarcodes technology for molecular diagnostics	185
Nanosensors	185
<i>Detection of cocaine molecules by nanoparticle-labeled aptasensors.....</i>	<i>185</i>
<i>Nanosensors for glucose monitoring</i>	<i>186</i>
<i>PEBBLE nanosensors</i>	<i>186</i>
<i>Quartz nanobalance biosensor.....</i>	<i>186</i>
DNA nanoswitch-linked immunosorbent assay	186
Quantum dot technology.....	187
<i>Qdot nanobarcode for multiplexed gene expression profiling.....</i>	<i>188</i>
Resonance Light Scattering technology	188
Role of nanobiotechnology in improving molecular diagnostics.....	189
Companies involved in nanomolecular diagnostics.....	189
Concluding remarks about nanodiagnostics	192
Future of nanodiagnostics	193
4. Proteomic Technologies for Molecular Diagnostics	195
Introduction	195
Proteomic technologies	195
Biomarkers of disease	195
<i>Proteomic tools for biomarkers</i>	<i>195</i>
<i>Search for biomarkers in body fluids.....</i>	<i>196</i>
Captamers with proximity extension assay for proteins.....	196
Cyclical amplification of proteins	196
Detection of misfolded proteins by ELISA with exponential signal amplification	197
Detection of proteins by Western blot	197
Diagnostics based on designed repeat proteins	197
Differential Peptide Display	198
Light-switching excimer probes.....	198
MALDI-TOF MS	199
Molecular beacon aptamer	199
Molecular beacon assay	200
Proteomic patterns.....	200
Real-time PCR for protein quantification.....	201
Protein biochip technologies.....	201
ProteinChip	202
LabChip for protein analysis	203
TRINECTIN proteome chip.....	203
Protein chips for antigen-antibody interactions molecular diagnostics	203
Microfluidic devices for proteomics-based diagnostics	204
Nanotechnology-based protein biochips/microarrays	204
<i>Nanoparticle protein chip</i>	<i>204</i>
<i>Protein nanobiochip.....</i>	<i>204</i>
<i>Protein biochips based on fluorescence planar wave guide technology</i>	<i>205</i>
New developments in protein chips/microarrays	206
<i>Antibody microarrays</i>	<i>206</i>
<i>Aptamer-based protein biochip</i>	<i>206</i>
<i>Multiplexed Protein Profiling on Microarrays.....</i>	<i>206</i>
<i>Proteomic pattern analysis</i>	<i>207</i>
<i>Single molecule array.....</i>	<i>207</i>
<i>Viral protein chip</i>	<i>207</i>
Commercial development of protein chips for molecular diagnostics	208
Proteome Identification Kit.....	209
Laser capture microdissection (LCM).....	210
LCM technology	210
Applications of LCM in molecular diagnostics	210
Proteomic diagnosis of CNS disorders.....	210
Cerebrospinal fluids tests based on proteomics	211

Urine tests for CNS disorders based on proteins in urine	211
Diagnosis of CNS disorders by examination of proteins in the blood.....	212
Diagnosis of CNS disorders by examination of proteins in tears.....	213
Role of proteomics in the diagnosis of Alzheimer's disease	213
Role of proteomics in the diagnosis of Creutzfeldt-Jakob disease.....	213
Future prospects of use of proteomics for diagnosis of CNS disorders	214
Concluding remarks on the use of proteomics in diagnostics.....	214

5. Molecular Diagnosis of Genetic Disorders	215
Introduction	215
Cytogenetics	216
FISH with probes to the telomeres	216
Single copy FISH probes	216
Comparative genomic hybridization	217
Use of biochips in genetic disorders.....	217
Representational oligonucleotide microarray analysis.....	218
Diagnosis of genomic rearrangements by multiplex PCR	218
Quantitative fluorescent PCR	218
Mutation detection technologies	219
PCR-based methods for mutation detection	220
<i>Cleavase Fragment Length Polymorphism</i>	<i>220</i>
<i>Direct dideoxy DNA sequencing</i>	<i>220</i>
<i>Digital Genetic Analysis (DGA).....</i>	<i>220</i>
<i>Fluorescence-based directed termination PCR.....</i>	<i>221</i>
<i>Fluorescence melting curve analysis for multiplex mutation detection</i>	<i>221</i>
<i>Heteroduplex analysis</i>	<i>222</i>
<i>Restriction fragment length polymorphism</i>	<i>222</i>
<i>Single-stranded conformation polymorphism (SSCP) analysis</i>	<i>222</i>
<i>TaqMan real-time PCR</i>	<i>223</i>
Non-PCR methods for mutation detection.....	223
<i>Arrayed primer extension.....</i>	<i>223</i>
<i>BEAMing (beads, emulsion, amplification, and magnetics).....</i>	<i>224</i>
<i>ELISA-protein truncation test</i>	<i>224</i>
<i>Enzymatic mutation detection.....</i>	<i>224</i>
<i>Specific anchor nucleotide incorporation</i>	<i>225</i>
<i>Conversion analysis for mutation detection</i>	<i>225</i>
Biochip technologies for mutation detection.....	225
<i>Combination of FISH and gene chips</i>	<i>226</i>
<i>Haplotype Specific Extraction</i>	<i>226</i>
Use of biosensors for detection of mutations	227
Technologies for SNP analysis	227
Acoustic detection of DNA conformation in genetic assays combined with PCR	228
DNA sequencing	228
Electrochemical DNA probes.....	229
<i>Use of NanoChip for detection of SNPs.....</i>	<i>229</i>
Single base extension-tag array.....	229
Laboratory Multiple Analyte Profile	229
SNP genotyping with gold nanoparticle probes.....	230
PCR-CTPP (confronting two-pair primers).....	230
PCR using one primer amplification of PCR-CTPP products.....	230
Peptide nucleic acid probes for SNP detection	231
SNP genotyping on a genome-wide amplified DOP-PCR template	231
Pyrosequencing	231
Reversed enzyme activity DNA interrogation test	232
Smart amplification process version 2	233
Zinc finger proteins	233
UCAN method (Takara Biomedical).....	233
Biochip and microarray-based detection of SNPs.....	233
SNP genotyping by MassARRAY	233
Electronic dot blot assay	234
Biochip combining BeadArray and ZipCode technologies	234
SNP-IT primer-extension technology	235
OmniScan SNP genotyping	235
Affymetrix SNP genotyping array	235
Concluding remarks on SNP genotyping.....	235
Limitations of SNP in genetic testing.....	236
Haplotyping versus SNP genotyping	236
Nanofluidics technology for high throughput SNP genotyping.....	237
Companies involved in developing technologies/products for SNP analysis	237
Role of copy number variations in genetic diagnostic testing	238

CNVs in various diseases	239
<i>CNVs in genetic epilepsy syndromes</i>	239
<i>CNVs associated with schizophrenia</i>	239
Methods for determination of CNVs	239
<i>Digital array for CNV detection</i>	240
<i>Wellcome Trust Case Control Consortium CNV typing array</i>	240
<i>CNVer algorithm for CNV detection</i>	240
<i>CNVnator for discovery of CNVs and genotyping</i>	241
Study of rare variants in pinpointing disease-causing genes	241
Chromothripsis and congenital abnormalities	242
Role of whole genome sequencing in screening of newborns	242
Prenatal DNA diagnosis	242
Invasive prenatal diagnostic procedures	243
<i>Amniocentesis</i>	243
<i>Chorionic villus sampling</i>	243
Molecular methods for prenatal diagnosis	243
<i>aCGH for prenatal diagnosis</i>	243
<i>BAC HD Scan test</i>	244
<i>FISH for prenatal diagnosis</i>	244
<i>PCR for prenatal diagnosis</i>	244
<i>In vivo gene expression analysis of the living human fetus</i>	245
Non-invasive prenatal molecular diagnostic procedures	245
<i>Fetal cells separation from maternal blood for genetic diagnosis</i>	245
<i>Digital relative mutation dosage in maternal plasma</i>	245
<i>Prenatal testing based on transrenal DNA from urine</i>	246
<i>Reflex DNA screening protocol</i>	246
Tests on fetal DNA in maternal blood	246
<i>Sequencing-based methods for prenatal diagnosis from maternal DNA</i>	246
<i>cfDNA testing vs routine screening in first trimester of pregnancy</i>	248
<i>Noninvasive WGS of the fetus</i>	249
<i>Directed DNA analysis of maternal blood</i>	250
Applications of prenatal diagnosis	250
<i>Antenatal screening for Down's syndrome</i>	251
<i>Diagnosis of congenital infections</i>	252
<i>Diagnosis of eclampsia</i>	252
<i>Identification of cancers in pregnant women during NIPT</i>	252
Preimplantation genetic diagnosis	253
Technologies for preimplantation genetic diagnosis	253
<i>PCR for preimplantation genetic diagnosis</i>	253
<i>FISH for preimplantation genetic diagnosis</i>	254
<i>Microarrays for preimplantation genetic diagnosis</i>	254
<i>Whole genome sequencing for PGD</i>	255
Conditions detected by preimplantation genetic diagnosis	255
The future of preimplantation genetic diagnosis	255
Companies involved in prenatal/preimplantation diagnosis	256
Cystic fibrosis	257
Detection of CFTR gene mutations	258
CFTR technologies of various companies	258
<i>Asuragen's bead array test</i>	259
<i>Ambry CF Test</i>	260
<i>Biochip for CF diagnosis</i>	260
<i>CF Plus™ Tag-It Cystic Fibrosis Kit</i>	260
<i>Genzyme's CF gene sequencing</i>	261
<i>HerediT™ (SEQUENOM) CF carrier screening test</i>	261
<i>Identification of CF variants by PCR/Oligonucleotide Ligation Assay</i>	261
<i>MiSeqDx sequencing-based CF assays</i>	261
<i>Serum proteomic signature for CF using antibody microarrays</i>	262
Guidelines for genetic screening for CF	262
Congenital adrenal hyperplasia	262
Primary immunodeficiencies	263
Hematological disorders	264
Hemoglobinopathies	264
<i>Sickle cell anemia</i>	264
<i>Thalassemia</i>	265
<i>Paroxysmal nocturnal hemoglobinuria</i>	265
Hemophilia	265
Hereditary hemochromatosis	265
Polycystic kidney disease	266
Hereditary metabolic disorders	266
Lesch-Nyhan Syndrome	266

Gaucher's Disease.....	267
Acute Intermittent Porphyria	267
Phenylketonuria.....	267
Hereditary periodic fever.....	268
Achondroplasia	268
Molecular diagnosis of eye diseases	268
Molecular diagnosis of retinitis pigmentosa.....	268
Genetic screening for glaucoma	269
Role of molecular diagnostics in rheumatoid arthritis.....	269
Molecular diagnosis of neurogenetic disorders	270
Alzheimer's disease	271
Autism spectrum disorders.....	272
<i>CNVs associated with autism</i>	272
Charcot-Marie Tooth disease	273
Down syndrome.....	274
Duchenne and Becker muscular dystrophy	274
eNOS gene polymorphisms as predictor of cerebral aneurysm rupture.....	275
Fragile X syndrome	275
Huntington disease	275
Hereditary neuropathy with liability to pressure palsies.....	276
Mitochondrial disorders affecting the nervous system	276
Parkinson's disease	277
Pompe's disease	278
Spinal muscular atrophy	278
Triple repeat disorders.....	279
Genetic testing for disease predisposition	279
Direct-to-consumer genetic tests	280
6. Molecular diagnosis of cardiovascular disorders.....	283
Introduction	283
Coronary heart disease.....	284
Genomics of coronary heart disease	284
Diagnosis of coronary artery disease based on gene expression	285
Cardiomyopathy.....	285
Hypertrophic cardiomyopathy	285
Idiopathic dilated cardiomyopathy.....	286
Cardiac arrhythmias	286
Genetic tests for cardiac arrhythmias	286
Long Q-T syndrome.....	286
Familial atrial fibrillation.....	287
Idiopathic ventricular fibrillation.....	287
Congestive heart failure.....	287
Hypertension	288
Disturbances of blood lipids.....	288
Familial dyslipoproteinemias.....	288
Hypercholesterolemia	288
Thrombotic disorders.....	289
Factor V Leiden mutation	289
Pulmonary embolism	290
Hereditary thrombophilia	290
Molecular diagnostics for monitoring heart transplant rejection.....	290
AlloMap® molecular expression testing.....	290
Commercial molecular diagnostics for cardiovascular disorders	291
7. Molecular Diagnosis of Infections	293
Introduction	293
Molecular techniques for the diagnosis of infections	293
Antibody-enhanced microplate hybridization assays	294
Bacteriophage-based methods for detection of bacteria	294
Biochips/microarrays for detection of microorganisms	295
<i>Lawrence Livermore Microbial Detection Array</i>	295
Biosensors for detection of microorganisms	295
<i>Ibis T5000™ Biosensor System</i>	295
<i>Molecular Mirroring Technology</i>	295
DNA enzyme immunoassay	296
DNA biochip/microarray in diagnosis of infections	296
DNA-based typing methods.....	297
<i>Restriction fragment length polymorphism analysis</i>	297
<i>Ribotyping</i>	297
<i>Random amplified polymorphic DNA</i>	297

<i>Combinatorial DNA melting assay</i>	297
Electrochemical detection of pathogens	298
Field Activated Sample Treatment (FAST)	298
FISH for detection of infections.....	298
<i>hemoFISH assay</i>	299
Helicase-dependent isothermal amplification for rapid detection of pathogens	299
High resolution melt analysis for diagnosis of infections	299
Immunomagnetic cell capture.....	299
Ligase chain reaction.....	300
Multiplex PCR for detection of infections.....	300
PCR electrospray ionization mass spectrometry	300
Metagenomic pyrosequencing.....	301
<i>Dual priming oligonucleotide for multiplex PCR</i>	302
<i>Multiplex amplified nominal tandem repeat analysis</i>	303
Tests for sepsis.....	303
<i>LightCycler® SeptiFast Test</i>	303
<i>NanoDx™</i>	304
<i>Next-generation sequencing assay to detect cell-free microbial DNA</i>	304
<i>SeptiCyte Triage assay</i>	304
<i>SepsiTest™</i>	305
<i>VYOO® Sepsis Test</i>	305
Nanopore-based diagnosis of infections	305
NASBA for detection of microorganisms	305
Nucleic acid probes	306
Neutrophil CD11b expression as a diagnostic marker.....	306
Optical Mapping	306
PNA-FISH for diagnosis of infections.....	307
Proteomic technologies for diagnosis of infections	307
<i>Mass spectrometry for microbial identification</i>	307
QuantiFERON® technology for pre-molecular diagnosis of infections	308
Quantitative reverse-transcription PCR for bacterial diagnostics	308
Rapid electrochemical diagnosis of infections.....	308
Rupture event scanning	309
Real-time single-molecule imaging of virus particles.....	309
Single-strand conformational polymorphism	309
SmartGene platform for identifying pathogens based on genetic sequences	309
Tessera array technology	310
Unyvero Solution	310
Applications, advantages and limitations of molecular diagnostics.....	310
Molecular diagnostics versus other microbial detection technologies	310
Advantages of nucleic acid-based diagnostics in infections	311
Drawbacks of nucleic acid-based diagnostics in infections	311
Nanotechnology for detection of infectious agents.....	312
Bacterial infections	312
Mycobacterium tuberculosis	316
<i>Conventional diagnosis of tuberculosis</i>	316
<i>Combined tuberculin testing and ELISpot^{PLUS} assay</i>	316
<i>Microscopic Observation Drug Susceptible Assay for tuberculosis</i>	317
<i>Molecular diagnostics for tuberculosis</i>	317
<i>Blood-based gene expression test for detecting TB</i>	319
<i>Diagnosis of TB in a POC setting</i>	319
<i>Diagnosis of drug-resistant MTB infection</i>	319
<i>GeneXpert MTB/RIF (eXpert) automated molecular test for MTB</i>	320
<i>QuantiFERON-TB Gold test</i>	321
Diagnosis of other mycobacteria	321
<i>Leprosy and M. leprae</i>	321
Bacteria associated with bacterial vaginosis.....	322
Chlamydial infections.....	322
Neisseria gonorrhoeae	324
Trichomonas vaginalis	324
Streptococcal infections	324
<i>Group B Streptococci</i>	324
<i>Group A Streptococcus and Streptococcus dysgalactiae</i>	325
Pseudomonas aeruginosa.....	325
Helicobacter pylori	326
Vibrio Cholerae	326
Lyme disease	326
Mycoplasmas.....	328
Fungal infections	328
PCR-based tests for fungal infections.....	329

DNA barcode marker for fungi	329
DNA sequencing for fungal infections.....	329
MALDI-TOF MS for diagnosis of fungal infections.....	330
Aspergillus	330
Candida species.....	330
Viral infections.....	331
Simultaneous testing of multiple viruses by VirScan	331
Carbon nanotubes-based detection of viruses.....	331
FDA-approved molecular diagnostics for viral infections	332
HIV/AIDS.....	333
<i>Diagnosis of HIV</i>	333
<i>Detection of HIV provirus</i>	334
<i>Global Surveillance of HIV-1 genetic variations</i>	334
<i>Genotyping for drug-resistance in HIV</i>	335
<i>Neonatal screening of infants of HIV-positive mothers</i>	336
<i>Phenotyping as predictor of drug susceptibility/resistance in HIV</i>	336
<i>POC testing for HIV</i>	337
<i>PCR for resolution of indeterminate Western blot</i>	337
<i>Screening of cadaveric tissue donors</i>	338
<i>Tests used for quantification of HIV</i>	338
<i>Conclusions about HIV diagnostics</i>	339
Hepatitis viruses	339
Hepatitis A virus	340
Hepatitis B virus	340
Hepatitis C virus	341
<i>Detection and quantification of HCV RNA</i>	341
<i>Quantification of HCV RNA levels as a guide to antiviral therapy</i>	342
<i>Electrochemical DNA chip for diagnosis of HCV</i>	342
<i>HCV Genotyping as a guide to therapy</i>	342
Hepatitis E	343
Enteroviruses	343
Adenoviruses.....	344
Rhinoviruses	344
Herpes viruses.....	345
<i>Herpes simplex virus</i>	345
<i>Genital and neonatal herpes simplex</i>	345
<i>Human cytomegalovirus infections</i>	346
<i>Epstein-Barr virus</i>	346
Human papilloma virus	347
<i>Molecular diagnostics for HPV</i>	347
Detection of encephalitis viruses	348
<i>West Nile and St. Louis encephalitis</i>	348
<i>Venezuelan equine encephalitis virus</i>	349
Detection of noroviruses	349
Detection of dengue virus	349
Detection of Ebola virus.....	350
Detection of Zika virus.....	350
Protozoal infections	351
Amebiasis	351
Cryptosporidium parvum.....	352
Leishmaniasis.....	352
Malaria	352
Neurocysticercosis	353
Pneumocystis carinii.....	353
Toxoplasmosis.....	353
Infections of various systems	354
CNS infections	354
<i>Molecular diagnosis in bacterial meningitis</i>	354
<i>Molecular diagnosis in herpes simplex encephalitis</i>	354
<i>Diagnosis of transmissible spongiform encephalopathies</i>	355
Molecular diagnosis of respiratory viruses	356
<i>Avian influenza H7N9</i>	357
<i>H1N1 influenza</i>	357
<i>Influenza viruses</i>	360
<i>Avian influenza H5N1</i>	362
<i>Respiratory syndromes associated with coronavirus</i>	365
Gastrointestinal infections	367
Periodontal infections	368
Diagnosis of urinary infections by a biosensor.....	369
Role of molecular diagnosis in sexually transmitted infections.....	369

Role of molecular diagnostics in septicemia	369
Limitations and needs of diagnostics for infections	370
Differentiation between live and antibiotic-killed bacteria	371
Cell-based methods for identifying pathogenic microorganisms	371
<i>Cell-based virus assays</i>	371
<i>Cell-based detection of host response to infection</i>	371
Role of molecular diagnostics in hospital acquired infections	372
Molecular diagnostics for detection of drug resistance in infections	372
Detection of hospital-acquired bacterial infections	372
<i>Detection of methicillin-resistant S. aureus</i>	372
<i>Whole-genome sequencing for investigation of MRSA outbreaks</i>	374
<i>Detection of carbapenemase-producing Gram-negative bacteria</i>	374
<i>Detection of vancomycin-resistant enterococci</i>	375
<i>Detection of hospital-acquired C. difficile</i>	375
<i>Integrated device for rapid detection of organisms associated HAI</i>	377
<i>Bacterial genome sequencing in antimicrobial resistance</i>	377
Detection of hospital-acquired viral infections	378
<i>Molecular diagnosis of BK virus</i>	378
<i>Diagnosis of hospital-acquired rotavirus gastroenteritis</i>	378
Molecular diagnostics and the microbiome	379
Human Microbiome Project.....	379
Application of metagenomics for study of the microbiome	379
MicroBiome Analysis Center	380
Concluding remarks and future of diagnosis of infections.....	380
Rapid point-of-care diagnosis of infections	381
Diagnosis of viruses using protein fingerprinting	384
QIAplex PCR multiplex technology.....	384
Role of PCR vs sequencing for diagnosis of infections.....	384
Companies involved in molecular diagnosis of infectious diseases	385

8. Molecular Diagnosis of Cancer	389
Introduction	389
Cancer genomics.....	389
Cancer genes	390
Oncogenes	390
Tumor Suppressor Genes.....	390
<i>BRCA mutations</i>	392
<i>p53</i>	392
<i>p16</i>	392
CNVs in cancer	392
<i>Allele-specific copy number analysis of tumors</i>	393
Viruses and cancer.....	393
<i>Detecting viral agents in cancer</i>	394
Conventional cancer diagnosis.....	395
Molecular techniques for cancer diagnosis.....	396
Exosome-based molecular diagnosis of cancer.....	397
Expression profiling of tumor cells sorted by flow cytometry	398
MicroRNA expression profiling for cancer diagnostics	398
Genome analysis at the molecular level	398
Mutation detection by sequencing	399
Quality control of NGS in oncology	399
Biomarkers in cancer	399
<i>Circulating nucleic acids as potential biomarkers of cancer</i>	400
<i>Circulating nucleosomes in serum of cancer patients</i>	400
<i>Detection of DNA methylation</i>	401
<i>eTag assay system for cancer biomarkers</i>	403
<i>HAAH as a biomarker for cancer</i>	403
<i>LigAmp for detection of gene mutations in cancer</i>	403
<i>Mitochondrial DNA as a cancer biomarker</i>	404
<i>Oncoproteins as biomarkers for cancer</i>	404
<i>Sequencing-based approaches for detection of cancer biomarkers</i>	405
Molecular fingerprinting of cancer	405
Fluorescent in situ hybridization.....	406
Genetic analysis of cancer	406
<i>Comparative genomic hybridization in cancer diagnostics</i>	406
<i>Loss of heterozygosity</i>	407
<i>Digital karyotyping</i>	407
<i>Gene expression profiles predict chromosomal instability in tumors</i>	408
PCR Techniques	408
<i>Cold-PCR</i>	408

<i>Real-time qPCR for diagnosis of cancer</i>	409
<i>Real-time PCR with myT™ Primer reagents</i>	409
Antibody-based diagnosis of cancer	409
<i>Monoclonal antibodies for diagnosis of cancer</i>	409
<i>Recombinant antibodies as a novel approach to cancer diagnosis</i>	410
Combined immunological and nucleic acid tests	410
<i>Combination of MAbs and RT-PCR</i>	410
<i>Immunobead RT-PCR</i>	410
Assays for determining susceptibility to cancer	411
Gene expression profiling in cancer	411
<i>Microarrays for gene expression profiling in cancer</i>	411
<i>Serial analysis of gene expression (SAGE)</i>	412
<i>Suppression subtractive hybridization</i>	412
<i>Cancer tests based on gene expression profiling</i>	412
Measurement of telomerase activity	413
Liquid biopsy for detection of circulating tumor cells in blood	414
<i>ApoStream for POC detection of CTCs</i>	414
<i>BEAMing technology for quantification of circulating tumor DNA</i>	414
<i>CEE (cell enrichment and extraction) technology</i>	415
<i>CellSearch</i>	415
<i>CellTracks® AutoPrep® System</i>	415
<i>CTCscope system for detection of CTCs</i>	416
<i>CTChip™</i>	416
<i>CTC sorting by acoustic waves</i>	416
<i>Detection of circulating tumor DNA</i>	416
<i>Droplet digital PCR for examination of cell free plasma DNA in cancer</i>	417
<i>DNA nanospheres for isolation of CTCs</i>	417
<i>Fiber-optic array scanning technology</i>	417
<i>Herringbone-chip for detection of CTCs</i>	418
<i>IsoFlux System</i>	418
<i>Lab-on-chip for the isolation and detection of CTCs</i>	418
<i>MagSweeper</i>	419
<i>Nano-Velcro to capture CTCs for diagnosis of cancer</i>	419
<i>NanoFlares for detection of CTCs</i>	419
<i>Companies developing tests for detection of CTCs</i>	419
<i>Future of detection of cancer cells in blood</i>	420
Epithelial aggregate separation and isolation	420
Proteomic technologies for the molecular diagnosis of cancer	421
<i>Proteomic technologies for tumor biomarkers</i>	421
<i>Affibodies as contrast agents for imaging in cancer</i>	421
<i>Aptamer-based technology for protein signatures of cancer cells</i>	422
<i>Aptamer probes for in vivo diagnosis of cancer</i>	422
<i>Aptamers for combined diagnosis and therapeutics of cancer</i>	423
<i>Automated image analysis of nuclear protein distribution</i>	423
<i>Laser capture microdissection in oncology</i>	423
<i>Layered expression scanning</i>	424
<i>Membrane-type serine protease-1</i>	424
<i>Survivin and molecular diagnosis of cancer</i>	425
Biochip/microarrays for cancer diagnosis	425
<i>Role of DNA microarrays in gene expression profiling</i>	426
<i>Biochip detection of FHIT gene</i>	426
Multiplexed single-cell analysis of FFPE cancer tissue samples	426
Nanobiotechnology for early detection of cancer	427
<i>Detection of nanoparticle self assembly in tumors by MRI</i>	427
<i>Differentiation between normal and cancer cells by nanosensors</i>	427
<i>Magnetic nanoparticle probes</i>	427
<i>Quantum dots for early detection of cancer</i>	428
Molecular imaging of cancer	429
<i>In vivo imaging of single cancer cells</i>	429
<i>In vivo molecular imaging of cancer</i>	429
<i>In vivo tumor illumination by adenoviral-GFP</i>	430
<i>PET for in vivo molecular diagnosis of cancer</i>	430
<i>Radiolabeled peptide-based targeting probes for cancer imaging</i>	431
<i>Xenon-enhanced MRI</i>	431
Detection of micrometastases	431
Detection of cancer stem cells	432
Detection of origin in cancers of unknown primary	432
Molecular diagnosis of cancers of various organs	433
Brain tumors	433
<i>Molecular diagnostic methods for brain tumors</i>	433

<i>Glioblastoma multiforme</i>	433
<i>Circulating microvesicles as biomarkers of glioblastoma</i>	434
<i>Circulating tumor cells in glioblastoma</i>	434
<i>Combination of neuroimaging and DNA microarray analysis in GBM</i>	435
<i>Medulloblastoma</i>	435
<i>Multigene predictor of outcome in GBM</i>	435
<i>Oligodendroglioma</i>	435
<i>Advantages and limitations of molecular diagnosis of brain tumors</i>	436
Breast cancer.....	436
<i>Breast cancer genes</i>	437
<i>Circulating tumor cells and nucleic acid biomarkers of breast cancer</i>	438
<i>Genomic profiles of breast cancer</i>	438
<i>Imaging biopsy specimens as alternative to histological examination</i>	439
<i>Microchimerism and breast cancer</i>	439
<i>Molecular diagnostic tests for breast cancer</i>	439
<i>Molecular diagnostics for management of breast cancer</i>	443
<i>Mouse ESC-based assays to evaluate mutations in BRCA2</i>	448
<i>One step nucleic acid amplification assay for breast sentinel nodes</i>	448
<i>Prognostic testing for of breast cancer</i>	448
<i>Prediction of recurrence in breast cancer for personalizing therapy</i>	450
Cervical cancer.....	452
Colorectal cancer.....	453
<i>ColoVantage CRC test</i>	453
<i>Detection of familial adenomatous polyposis coli</i>	453
<i>Detection of CRC at precancerous state</i>	453
<i>Detection of circulating tumor cells in CRC</i>	454
<i>Diagnosis of hereditary nonpolyposis CRC</i>	454
<i>Diagnosis of CRC from DNA in stools</i>	455
<i>Droplet Digital™ PCR for detection of KRAS Mutations</i>	455
<i>Early diagnosis of CRC from blood samples</i>	455
<i>Guanylyl cyclase C-based tests for CRC</i>	456
<i>Minimally invasive screening for CRC</i>	456
<i>Multitarget stool DNA testing for CRC screening</i>	457
Gastric cancer.....	457
Head and neck cancer.....	457
<i>Nanobiochip sensor technique for analysis of oral cancer biomarkers</i>	457
<i>ProteinChip for diagnosis of head and neck cancer</i>	458
Hematological malignancies.....	458
<i>Chromosome translocations</i>	458
<i>Flow cytometry in diagnosis of leukemia</i>	459
<i>Gene chip technology</i>	459
<i>Hairy-cell leukemia</i>	459
<i>Laboratory assessment of leukemia</i>	459
<i>Molecular probes</i>	460
<i>Minimal residual disease</i>	461
<i>Molecular diagnosis in myelodysplastic syndromes</i>	461
<i>Screening of gene mutations in chronic myeloproliferative diseases</i>	462
Lung cancer.....	462
<i>Molecular subtyping of lung cancer</i>	464
Melanoma.....	465
Ovarian cancer.....	465
<i>Mutation of genes</i>	466
<i>Relevance of genetic testing to management of ovarian cancer</i>	466
<i>Serum biomarkers for early detection of ovarian cancer</i>	466
<i>Biomarkers of ovarian cancer</i>	466
<i>Concluding remarks on testing for ovarian cancer</i>	467
Pancreatic cancer.....	468
<i>Proteomic techniques for diagnosis of pancreatic cancer</i>	468
<i>Detection of KRAS mutations in pancreatic cancer</i>	468
Prostate cancer.....	468
<i>Identification of genetic risks for prostate cancer</i>	469
<i>Gene expression analysis of prostate cancer</i>	469
<i>Huntingtin Interacting Protein 1</i>	469
<i>Integrative genomic and proteomic profiling of prostate cancer</i>	469
<i>LCM for diagnosis of prostate cancer</i>	470
<i>Liquid biopsy for prostate cancer patients</i>	470
<i>Nanotechnology for early detection of recurrence of prostate cancer</i>	471
<i>PCA3 gene detection in urine</i>	471
<i>PCR assay for assessing silencing of protein cadherin 13 gene</i>	472
<i>Prolaris test</i>	472

Prostate biopsy for detection of prostatic intraepithelial neoplasia	472
Prostate Core Mitomic Test™	472
Prostat Health Index	473
Screening of multiple SNPs for risk of prostate cancer	473
Semen testing for prostate cancer biomarkers	473
Serum-protein fingerprinting in prostate cancer	474
Thyroid cancer	474
<i>Afirma</i> gene expression classifier for inconclusive thyroid biopsies	474
Gene expression biomarkers of thyroid cancer	474
Multiple endocrine neoplasia type 2B as risk factor for thyroid cancer	475
miRNA expression profiling in thyroid cancer	475
Urinary bladder cancer	476
Role of molecular diagnostics in the management of cancer	476
Risk assessment and prevention of cancer	476
Role of molecular diagnosis in the design of future cancer therapies	477
Molecular classification of cancer	477
Determination of cancer prognosis	478
<i>Prognosis by tumor classification</i>	478
<i>Prognosis by cancer gene expression</i>	478
Selection of anticancer drugs based on molecular diagnosis	478
Integrated genome-wide analysis of cancer for diagnosis and therapy	479
Personalized therapy for cancer patients	479
Pharmacogenetics and cancer therapy	480
Molecular diagnostics as an aid to selection of cancer therapy	480
Drug resistance in cancer	481
Role of organizations in molecular diagnosis of cancer	481
Role of NCI in molecular diagnosis of cancer	481
<i>Molecular profiling of cancer</i>	481
<i>Cancer Genome Atlas</i>	482
<i>Cancer Genetic Markers of Susceptibility Project</i>	483
<i>Support for future research in molecular diagnosis of cancer</i>	483
Role of the International Cancer Genome Consortium	483
Future prospects of molecular diagnosis of cancer	484
Companies involved in molecular diagnosis of cancer	484

9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare ... 489

Introduction	489
Molecular diagnostics in biopharmaceutical industry	489
Molecular diagnostic technologies and drug discovery	490
Molecular diagnostics and pharmacogenetics	490
Molecular toxicology	491
<i>Gene expression studies for toxicology</i>	492
<i>Toxicogenomics</i>	492
<i>Toxicoproteomics</i>	493
Mitochondrial assays	494
MetaChip/Datachip	494
Molecular diagnostics and pharmacogenomics	495
Molecular diagnostics and therapeutic drug monitoring	496
Applications molecular diagnostics in gene therapy	496
<i>Use of PCR to study biodistribution of gene therapy vectors</i>	496
<i>PCR for verification of the transcription of DNA</i>	497
<i>In situ PCR for direct quantification of gene transfer into cells</i>	497
<i>Detection of retroviruses by reverse transcriptase (RT)-PCR</i>	497
<i>Assessment of safety issues of gene transfer</i>	497
<i>Quantitative PCR for monitoring the effectiveness of gene therapy</i>	498
<i>Use of FISH for analysis of adeno-associated viral vector integration</i>	498
<i>Monitoring of gene expression by green fluorescent protein</i>	498
Quality control of protein therapeutics and vaccines	498
Detection of microbial contamination in biopharmaceutical manufacturing	499
<i>Role of PCR in detecting contamination</i>	499
<i>Systems for rapid detection of contaminants</i>	499
<i>Contamination of biopharmaceuticals with prions</i>	500
DNA tagging for control and tracing of drug distribution channels	500
Molecular diagnostics for organ transplantation	501
HLA typing	501
Sequencing for HLA typing	502
Commercial products for transplant molecular diagnostics	502
Post-cardiac transplant patient monitoring for rejection	504
Application of molecular diagnostics in blood transfusion	505
Molecular diagnostics for testing transfusion compatibility	505

Transmission of infections in blood transfusion	506
Molecular tests for screening of blood supply for viruses	506
Commercial molecular diagnostic technologies for blood screening	507
<i>Bridge amplification technology</i>	507
<i>COBAS AmpliScreen HCV and HIV Assays</i>	508
<i>INACTINE</i>	508
<i>NucliSens Extractor system</i>	508
<i>Pall's enhanced Bacteria Detection System</i>	509
<i>PCR combined with algorithm method</i>	509
<i>Prions detection in human blood</i>	509
<i>PRISM® automated system</i>	510
<i>Procleix HIV-1/HCV Assay</i>	510
<i>West Nile virus detection in human blood</i>	511
Advantages and limitations of molecular diagnostics for blood screening	511
Molecular epidemiology	512
Molecular epidemiology of genetic diseases	512
<i>Role of CNVs in study of genetic epidemiology</i>	513
<i>Accumulation of CNVs with aging</i>	513
<i>Monogenic versus polygenic disorders</i>	514
<i>Critical issues facing genetic epidemiology</i>	514
Molecular epidemiology of infectious diseases	514
<i>Methods and purposes</i>	514
<i>Emerging infections</i>	515
<i>Human vs. non-human infections</i>	516
<i>Genetics and susceptibility to infectious disease</i>	516
Molecular epidemiology of cancer	516
<i>Molecular epidemiology of p53 gene mutations</i>	517
<i>Molecular epidemiology of link between virus and cancer</i>	517
<i>Molecular epidemiology and cancer prevention</i>	517
<i>SNPs and molecular epidemiology</i>	518
Molecular diagnostics for identification of food-borne pathogens	518
Introduction	518
Molecular diagnostic methods used in food-borne infections	518
Limitations of use of molecular probes in food analysis	519
Detection of Listeria-contaminated foods	520
<i>Optical biosensor for detection of Listeria</i>	520
<i>Real-time PCR for detection of Listeria</i>	520
<i>Sequencing for investigation of food-borne Listeria infections</i>	521
Detection of Salmonella	521
<i>MicroSEQ® Salmonella Detection Kit</i>	521
E. Coli detection	521
<i>MicroSEQ® E. Coli Detection Kit</i>	521
<i>DuPont Bax system</i>	521
<i>MLG method for detection of multiple STEC strains</i>	522
<i>Detection of rare strains of E. Coli</i>	522
Companies with technologies for food pathogen detection	523
Transmissible spongiform encephalopathies (TSEs)	525
<i>Basis of molecular diagnosis of prion diseases</i>	525
<i>Molecular diagnosis of TSEs</i>	526
<i>Companies involved in developing molecular diagnostics for TSEs</i>	529
Detection of genetically modified food	530
Molecular diagnostics for detection of doping in sports	531
Screening of synthetic glucocorticosteroids in human urine	531
Detection of gene doping	532
Role of molecular diagnostics in future healthcare	532
Translation of genomic research into genetic testing for healthcare	532
Molecular diagnostics and disease management	533
Role of genetic biomarkers in disease management	533
Role of molecular diagnostics in personalized medicine	533
Integrated healthcare	534
<i>Screening</i>	534
<i>Early diagnosis</i>	534
<i>Prevention</i>	535
<i>Therapy based on molecular diagnosis</i>	535
<i>Monitoring of therapy</i>	535
<i>Advantages and limitations of integrated healthcare</i>	535
<i>Commercially available systems for integrated healthcare</i>	536
Combination of diagnostics and therapeutics	536
<i>Companion diagnostics</i>	536
<i>Companies involved in companion diagnostics</i>	537

Point-of-care diagnosis	538
<i>Advantages versus disadvantages of POC diagnosis</i>	540
<i>Technologies for point-of-care diagnosis</i>	540
<i>Biochips for POC diagnosis</i>	542
<i>CRISPR for POC diagnosis</i>	543
<i>Mobile detection of infections by microfluidic LAMP and smartphone</i>	544
<i>Nanosensors for POC diagnosis</i>	544
<i>POC Diagnostic Initiative</i>	544
<i>Paper-based POC diagnostic for infectious diseases</i>	545
<i>Synthetic biomarker-based POC diagnostic for cancer</i>	545
<i>Future prospects of POC testing</i>	545
<i>Companies developing POC diagnosis</i>	546
The impact of molecular diagnostics on clinical laboratory practice	548

10. Molecular Diagnostics in Forensic Medicine and Biological Warfare .. 551

Application of molecular diagnostics in forensic medicine	551
Technologies	551
<i>ABO genotyping</i>	551
<i>DNA analysis for identification of ancient or historical specimens</i>	552
<i>DNA fingerprinting and short tandem repeats</i>	552
<i>DNA processing of forensic samples</i>	553
<i>DNA profiles from fingerprints</i>	553
<i>Fluorescent detection systems</i>	554
<i>Genome wide association studies linking genes to facial features</i>	554
<i>Mitochondrial DNA analysis</i>	554
<i>Next generation sequencing for forensic diagnosis</i>	555
<i>Pressure cycling technology for forensic applications</i>	556
<i>Polymorphic Alu insertions</i>	556
<i>SNP analysis</i>	556
Applications	556
<i>Applications in criminology</i>	557
<i>Identification of remains of military personnel</i>	558
<i>Identification of remains of victims of mass disasters</i>	558
<i>Parentage testing</i>	560
<i>Gender determination</i>	561
Companies developing molecular diagnostics for forensic science.....	561
Molecular detection of biological warfare agents.....	562
Introduction to biological warfare agents	562
Role of PCR in the diagnosis of biological warfare agents.....	563
<i>Multiplex PCR microarray assay to detect bioterror pathogens in blood</i>	564
Laboratory diagnosis of Anthrax.....	564
Challenges in diagnosis of biological warfare agents	565
US government efforts for detection of biological warfare agents	565
<i>The US Army Medical Research Institute of Infectious Diseases</i>	566
<i>Homeland Security Advance Research Projects Agency</i>	567
<i>Handheld Isothermal Silver Standard Sensor</i>	567
<i>Hapten mediated display and pairing of rAbs for biothreat assays</i>	567
Commercial development of diagnostic devices for biological agents.....	568
<i>Companies developing diagnostic devices for biological agents</i>	568
Various devices for testing	570
<i>Airborne bacterial spore detection technology</i>	570
<i>Analyte 2000 biosensor</i>	570
<i>Bead ARray Counter</i>	571
<i>Benchtop living cell biosensor</i>	571
<i>BioThreat Alert Test Strip</i>	571
<i>BioForce NanoArray sensor technology</i>	572
<i>Biodefence microarray</i>	572
<i>Biosensor based on mass spectrometry of microorganisms's RNA</i>	573
<i>Destruction and detection of anthrax by lysin</i>	573
<i>Hand-Held Advanced Nucleic Acid Analyzer</i>	573
<i>Identification of genetic markers of individual pathogens</i>	573
<i>Microbial Identification System based on OptiChip™</i>	574
<i>MicroChemLab</i>	574
<i>Nanode Array Sensor Microchips</i>	575
<i>ProteinChip-based detection of bioterrorism agents</i>	575
<i>QTL handheld biosensor</i>	575
<i>TIGER biosensor</i>	575
<i>The PathAlert™ Detection System</i>	576
<i>VereThreat™</i>	576
Concluding remarks about biodefense applications of diagnostics	576

Tables

Table 1-1: Landmarks in development of molecular technology and its application to diagnosis 27

Table 1-2: Applications of molecular diagnostics 50

Table 2-1: Companies with products for nucleic acid isolation 60

Table 2-2: Applications of real-time PCR 69

Table 2-3: Some commercially available real-time PCR systems 72

Table 2-4: A selection of companies with commercially available FISH diagnostics 102

Table 2-5: Selected companies with RNA diagnostic tests 103

Table 2-6: Companies involved in whole genome amplification 113

Table 2-7: Companies involved in application of sequencing in molecular diagnostics 116

Table 2-8: Comparison of methods of identification of unknown DNA sequences 119

Table 2-9: Classification of methods of gene expression analysis 121

Table 2-10: A selection of companies with gene expression technologies 126

Table 2-11: Companies involved in developing PNA diagnostics 130

Table 2-12: Companies with bead-based diagnostic assay platforms 134

Table 2-13: Companies developing nucleic acid lateral flow molecular diagnostics 136

Table 3-1: Applications of biochip technology in relation to molecular diagnostics 139

Table 3-2: Companies developing whole genome chips/microarrays 145

Table 3-3: Companies involved in biochips for molecular diagnostics 146

Table 3-4: Companies developing microfluidic technologies 152

Table 3-5: Biosensor technologies with potential applications in molecular diagnostics 153

Table 3-6: Important applications of biosensors 163

Table 3-7: Companies involved in application of biosensors in molecular diagnostics 164

Table 3-8: Selected labels for nucleic acid detection 165

Table 3-9: Selected companies with fluorescence and chemiluminescence products 167

Table 3-10: Companies involved in molecular beacon manufacture and research 169

Table 3-11: Selected companies involved in molecular imaging 178

Table 3-12: Nanotechnologies with potential applications in molecular diagnostics 179

Table 3-13: Companies developing nanomolecular diagnostics 189

Table 4-1: Applications of protein biochips/microarrays 201

Table 4-2: Companies involved in developing diagnostic applications of protein biochips 208

Table 4-3: Disease-specific proteins in the cerebrospinal fluid of patients 211

Table 5-1: Mutation detection technologies 219

Table 5-2: Technologies for SNP analysis 227

Table 5-3: A sampling of companies involved in technologies for SNP genotyping 237

Table 5-4: Application of preimplantation genetic diagnosis in monogenic disorders 255

Table 5-5: Companies involved in prenatal/preimplantation diagnostics 256

Table 5-6: CFTR genotyping in cystic fibrosis – companies and technologies 258

Table 5-7: X-linked immunodeficiency disorders 263

Table 5-8: Available molecular diagnostics for neurogenetic diseases 270

Table 5-9: Companies offering genetic screening tests directly to consumers 280

Table 6-1: Genes that cause cardiovascular diseases 283

Table 6-2: Molecular diagnostics for cardiovascular diseases: commercial development 291

Table 7-1: Molecular techniques for the diagnosis of infections 293

Table 7-2: Commercially available molecular diagnostics for *sepsis* 303

Table 7-3: FDA-approved molecular diagnostics for various bacterial infections 312

Table 7-4: Commercially available molecular diagnostics for fungal infections 328

Table 7-5: FDA-approved molecular diagnostics for viral infections 332

Table 7-6: Companies with molecular diagnostics for influenza virus H1N1 358

Table 7-7: Companies with molecular diagnostics for avian influenza virus H5N1 362

Table 7-8: Commercially available molecular diagnostics for *C. difficile* 377

Table 7-9: Companies developing POC tests for the diagnosis of infections 381

Table 7-10: Selected companies involved in molecular diagnosis of infections 385

Table 8-1: Estimated new cases of cancer in the US of most involved organs - 2013 389

Table 8-2: Tumor suppressor genes, their chromosomal location, function, and associated tumors 391

Table 8-3: Viruses linked to human cancer 394

Table 8-4: A classification of molecular diagnostic methods in cancer 396

Table 8-5: Desirable characteristics of biomarkers for cancer 400

Table 8-6: Approved monoclonal antibodies for cancer diagnosis 410

Table 8-7: Methods for comparison of gene-expression profiling in tumor specimens 411

Table 8-8: Important cancer tests based on gene signatures 413

Table 8-9: Companies developing technologies for detection of CTCs 420

Table 8-10: Impact of in vivo molecular imaging of cancer on oncology practice 430

Table 8-11: Molecular diagnostic tests for breast cancer 439

Table 8-12: Companies developing cancer molecular diagnostics 484

Table 9-1: Applications of molecular diagnostics in the biopharmaceutical industry	489
Table 9-2: Molecular diagnostic technologies for drug discovery	490
Table 9-3: Molecular diagnostic technologies used for pharmacogenetic studies.....	490
Table 9-4: Companies with novel molecular toxicology technologies	491
Table 9-5: Applications of molecular diagnostics in gene therapy	496
Table 9-6: Companies involved in transplant molecular diagnostics	502
Table 9-7: Companies involved in molecular diagnostics of blood transfusions.....	507
Table 9-8: Pathogenic bacteria in food and targets for molecular diagnostic probes.....	519
Table 9-9: Companies involved in molecular diagnostics for food-borne infections	524
Table 9-10: Testing for harmful prions in brain tissue from dead cattle.....	526
Table 9-11: Companies involved in developing molecular diagnostics for TSEs	529
Table 9-12: Companies involved in detection of genetically modified food	530
Table 9-13: Companies involved in companion diagnostics.....	537
Table 9-14: Applications of point-of-care diagnosis	539
Table 9-15: Companies developing point-of-care diagnostic tests	546
Table 10-1: Forensic and legal applications of molecular diagnostics.	556
Table 10-2: Molecular technologies used for forensic applications	562
Table 10-3: Biological and chemical agents used as weapons of mass destruction.....	563
Table 10-4: Biological warfare agents that can be identified by PCR methods.....	563
Table 10-5: Companies developing devices for detection of biological warfare agents.....	568

Figures

Figure 1-1: Relation of molecular diagnostics to other technologies.....	51
Figure 2-1: MNAAzyme qPCR	74
Figure 2-2: Rolling circle amplification technology.....	84
Figure 2-3: A schematic view of the Invader operating system	92
Figure 2-4: Principle of fluorescent in situ hybridization	97
Figure 2-5: Repli-G system of QIAGEN	114
Figure 2-6: DNA sequencing process.....	115
Figure 2-7: Electrochemical detection of DNA	133
Figure 2-8: Elements of a Scorpions primer	135
Figure 3-1: Affymetrix GeneChip technology	140
Figure 3-2: Basic principle of a biosensor.....	153
Figure 3-3: Surface plasmon resonance (SPR) technology.....	158
Figure 7-1: Use of DNA chips in diagnosing microbial infections.....	296
Figure 7-2: High throughput DNA pyrosequencing for pathogen discovery	302
Figure 9-1: The mechanism of SHERLOCK for POC diagnosis.....	543